A Phase 1/2 Study of ASP1570 in Participants with Locally Advanced or Metastatic Solid Tumors
NCT #
NCT05083481
Condition(s)
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor
Molecular Target(s)
DAG (DGK)
Drug Classification(s)
Immunotherapy (Targeted), Small Molecule
Agents(s)
ASP1570
Phase(s)
I
Mechanism of Action
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Purpose
- How much of the study drug can be given alone and in combination with Pembro with an acceptable level of side effects
- The effects of the study drug alone and in combination with Pembro (good and bad)
- How much of the study drug alone and in combination with Pembro is absorbed into the blood and how fast it is removed
- If the study drug alone and in combination with Pembro prevents or slows tumor growth or shrinks existing tumors
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.